Mapping the N6-methyladenosine (m6A) transcriptome in prostate cancer has established its clinical potential value as a prognostic biomarker for this disease. A multidisciplinary approach that integrates genomics, transcriptomics, epitranscriptomics, proteomics and clinical oncology is essential to translate the intricacies of m6A modification into tangible benefits for patients.
